Publications by authors named "Bridgette Andrew"
Background/aims: Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulcerative colitis in a real-world population.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the effectiveness of infliximab treatment in patients with steroid-refractory acute severe ulcerative colitis (ASUC) and examine the relationships of specific serum biomarkers with the need for colectomy.
- A total of 94 patients were analyzed, and the results showed that 20% required colectomy within 12 months, with day 3 post-infliximab biomarkers like CRP-albumin-ratio (CAR) and CRP-lymphocyte-ratio (CLR) being significant indicators for predicting nonresponse and potential colectomy.
- The findings suggest that CAR and CLR can serve as effective predictive tools for colectomy risk, highlighting the need for further studies to validate these biomarkers
Smoking is a major preventable cause of adverse outcomes in pregnancy. Despite the existence of smoking cessation support guidelines, many pregnant smokers do not receive support in quitting. The aim of this study was to identify and understand the facilitators and barriers experienced by GPs in implementing the 5As of smoking cessation support with pregnant women.
View Article and Find Full Text PDF